Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y6A1
UPID:
POMT1_HUMAN
Alternative names:
Dolichyl-phosphate-mannose--protein mannosyltransferase 1
Alternative UPACC:
Q9Y6A1; B3KQG0; B4DIF0; Q5JT01; Q5JT06; Q5JT08; Q8NC91; Q8TCA9; Q9NX32; Q9NX82; Q9UNT2
Background:
Protein O-mannosyl-transferase 1, also known as Dolichyl-phosphate-mannose--protein mannosyltransferase 1, plays a crucial role in transferring mannosyl residues to serine or threonine residues. This process requires the coexpression of POMT1 and POMT2 for enzyme activity, highlighting its specificity towards O-mannosylation of alpha-DAG1 and a select few proteins.
Therapeutic significance:
Linked to various forms of muscular dystrophy-dystroglycanopathy, including congenital forms with impaired intellectual development and limb-girdle types, understanding the role of Protein O-mannosyl-transferase 1 could open doors to potential therapeutic strategies for these debilitating conditions.